ClinicalTrials.gg
CompletedNCT05773053PAOLAUpdated Nov 10, 2026Results posted

A Study of NT 201 Doses in the Treatment of Platysma Prominence

A Phase 2 interventional study of NT 201 and NT 201 Placebo in Platysma Prominence, sponsored by Merz Aesthetics GmbH. Completed at 7 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Merz Aesthetics GmbH (part of Merz Pharma) · Phase 2, Interventional, and Treatment

Updated Nov 10, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety and efficacy of NT 201 in adults with moderate to severe platysma prominence.

02

Conditions studied

  • Platysma Prominence
03

In context

Lead sponsor

Merz Aesthetics GmbH is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of four (medial and lateral, left and right) prominent platysmal bands
  • Moderate to severe platysmal bands as assessed by the investigator and subject on the MAPS-D at maximum contraction

Exclusion criteria

Exclusion Criteria:

  • Any serious disease or disorder (medical or psychiatric) that could interfere with the safe completion of treatment or compromise subject safety
  • Botulinum toxin treatment in the face (below the lower orbital rim), neck, or chest within the last 12 months prior to study treatment
  • History of lower face surgery, neck or chest surgery, aesthetic procedures (e.g., ablative skin resurfacing, laser, chemical peel, micro-focused ultrasound, deoxycholic acid injections, micro-needling, non-surgical fat reduction procedure), and orthodontic procedures (e.g., braces) in the 12 months prior to study treatment
  • Previous use of any permanent (non-biodegradable) or semi-permanent (e.g., calcium hydroxylapatite, poly-L-lactic acid, polymethyl methacrylate, etc.) facial tissue augmentation therapy, lifting sutures, permanent implants or autologous fat to the lower face (i.e., below the level of the bottom of the nose), neck, or chest within 24 months prior to study treatment
  • Previous use of any hyaluronic acid based or collagen based biodegradable facial tissue augmentation therapy to the lower face (i.e., below the level of the bottom of the nose), neck, or chest within 12 months prior to study treatment
  • Any medical condition that may put the subject at increased risk with exposure to botulinum toxin of any serotype, including myasthenia gravis, Lambert-Eaton-Syndrome, amyotrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function
  • Female of not using a highly effective method of , planning to get pregnant, or pregnant or lactating
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    NT 201 Dose 1

    Subjects will receive Dose 1.

    Drug: NT 201

  • Experimental
    NT 201 Dose 2

    Subjects will receive Dose 2.

    Drug: NT 201

  • Experimental
    NT 201 Dose 3

    Subjects will receive Dose 3.

    Drug: NT 201

  • Placebo comparator
    Placebo

    Subjects will receive matching placebo.

    Drug: NT 201 Placebo

Interventions

  • DrugNT 201

    Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.

    Also known as: IncobotulinumtoxinA, Xeomin/Bocouture, Xeomin Cosmetic, Xeomeen

  • DrugNT 201 Placebo

    NT 201 Matching-placebo.

06

What researchers measure

Primary outcomes

  1. Change From Baseline on the Merz Aesthetic Platysma Scale-Dynamic (MAPS-D) Score at Maximum Contraction as Assessed Live by the Investigator at Week 2

    The platysma area was assessed live by the investigator at maximum contraction and graded according to the validated five-point MAPS-D. Scores ranged from Grade 1 (none to minimal) to Grade 5 (very severe). The higher score indicated severe outcomes, and a negative change indicated improvements.

    Time frame: Baseline and Week 2

Secondary outcomes

  1. Change From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Subject at Week 2

    The platysma area was assessed live by the subject at maximum contraction and graded according to the validated five-point MAPS-D. Scores ranged from Grade 1 (none to minimal) to Grade 5 (very severe). The higher score indicated severe outcomes, and a negative change indicated improvements.

    Time frame: Baseline and Week 2

  2. Number of Subjects With Related Treatment Emergent Adverse Events (TEAEs)

    TEAEs were defined as adverse events (AEs) with onset or worsening on or after date of first dose of study treatment. An TEAE was considered to be "related" to IP(s) if a causal relationship between the IP(s) and an TEAE was at least a reasonable possibility (i.e., the relationship cannot be ruled out).

    Time frame: From first dose of study drug up to Week 17

07

Results

Posted Nov 10, 2026

Participant flow

Subjects were recruited from 7 investigational sites in the United States.

Participant flow — Overall Study
MilestoneGroup 1: Dose 1 NT201Group 2: Dose 2 NT201Group 3: Dose 3 NT201Group 4: Placebo
Started16171718
Treated- safety evaluation set (ses)17161718
Completed16141718
Not completed0300
Withdrew: Lost to follow-up0100
Withdrew: Subject relocated0200

Outcome measures

PrimaryChange From Baseline on the Merz Aesthetic Platysma Scale-Dynamic (MAPS-D) Score at Maximum Contraction as Assessed Live by the Investigator at Week 2

The platysma area was assessed live by the investigator at maximum contraction and graded according to the validated five-point MAPS-D. Scores ranged from Grade 1 (none to minimal) to Grade 5 (very severe). The higher score indicated severe outcomes, and a negative change indicated improvements.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Merz Aesthetic Platysma Scale-Dynamic (MAPS-D) Score at Maximum Contraction as Assessed Live by the Investigator at Week 2
score on a scaleGroup 1: Dose 1 NT201Group 2: Dose 2 NT201Group 3: Dose 3 NT201Group 4: Placebo
Change From Baseline on the Merz Aesthetic Platysma Scale-Dynamic (MAPS-D) Score at Maximum Contraction as Assessed Live by the Investigator at Week 2-1.511 ± 0.1880-1.874 ± 0.1847-1.437 ± 0.1791-0.303 ± 0.1758
Statistical analysis
  • Group 1: Dose 1 NT201 vs Group 4: Placebo · ANCOVA · p = < 0.0001p-value from two-sided test for the NT 201 group and placebo at alpha = 0.05.
  • Group 2: Dose 2 NT201 vs Group 4: Placebo · ANCOVA · p = < 0.0001p-value from two-sided test for the NT 201 group and placebo at alpha = 0.05.
  • Group 3: Dose 3 NT201 vs Group 4: Placebo · ANCOVA · p = < 0.0001p-value from two-sided test for the NT 201 group and placebo at alpha = 0.05.
SecondaryChange From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Subject at Week 2

The platysma area was assessed live by the subject at maximum contraction and graded according to the validated five-point MAPS-D. Scores ranged from Grade 1 (none to minimal) to Grade 5 (very severe). The higher score indicated severe outcomes, and a negative change indicated improvements.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · score on a scale
Change From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Subject at Week 2
score on a scaleGroup 1: Dose 1 NT201Group 2: Dose 2 NT201Group 3: Dose 3 NT201Group 4: Placebo
Change From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Subject at Week 2-1.378 ± 0.2239-1.230 ± 0.2192-1.225 ± 0.2133-0.664 ± 0.2094
Statistical analysis
  • Group 1: Dose 1 NT201 vs Group 4: Placebo · ANCOVA · p = 0.0199p-value from two-sided test for the NT 201 group and placebo at alpha = 0.05.
  • Group 2: Dose 2 NT201 vs Group 4: Placebo · ANCOVA · p = 0.0595p-value from two-sided test for the NT 201 group and placebo at alpha = 0.05.
  • Group 3: Dose 3 NT201 vs Group 4: Placebo · ANCOVA · p = 0.0619p-value from two-sided test for the NT 201 group and placebo at alpha = 0.05.
SecondaryNumber of Subjects With Related Treatment Emergent Adverse Events (TEAEs)

TEAEs were defined as adverse events (AEs) with onset or worsening on or after date of first dose of study treatment. An TEAE was considered to be "related" to IP(s) if a causal relationship between the IP(s) and an TEAE was at least a reasonable possibility (i.e., the relationship cannot be ruled out).

Time frame:
From first dose of study drug up to Week 17
Reported as:
Count of participants · Participants
Number of Subjects With Related Treatment Emergent Adverse Events (TEAEs)
ParticipantsGroup 1: Dose 1 NT201Group 2: Dose 2 NT201Group 3: Dose 3 NT201Group 4: Placebo
Number of Subjects With Related Treatment Emergent Adverse Events (TEAEs)1011

Adverse events

Collected over From the first dose of study drug up to Week 17. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Dose 1 NT2010/17 (0%)0/17 (0%)3/17 (17.6%)
Group 2: Dose 2 NT2010/16 (0%)1/16 (6.3%)4/16 (25%)
Group 3: Dose 3 NT2010/17 (0%)0/17 (0%)4/17 (23.5%)
Group 4: Placebo0/18 (0%)1/18 (5.6%)4/18 (22.2%)
Most frequent serious events
Most frequent serious events
EventGroup 1: Dose 1 NT201Group 2: Dose 2 NT201Group 3: Dose 3 NT201Group 4: Placebo
CholecystitisHepatobiliary disorders0/171/160/170/18
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/170/160/171/18
Most frequent other events
Showing 10 of 28
Most frequent other events
EventGroup 1: Dose 1 NT201Group 2: Dose 2 NT201Group 3: Dose 3 NT201Group 4: Placebo
Influenza like illnessGeneral disorders0/171/160/170/18
Blood pressure diastolic increasedInvestigations0/171/160/170/18
Muscle spasmsMusculoskeletal and connective tissue disorders0/171/160/170/18
AnaemiaBlood and lymphatic system disorders0/171/160/170/18
AnxietyPsychiatric disorders0/171/160/170/18
DyspnoeaRespiratory, thoracic and mediastinal disorders0/171/160/170/18
Injection site bruisingGeneral disorders1/170/161/171/18
Blood creatine phosphokinase increasedInvestigations0/170/161/170/18
Gamma-glutamyltransferase increasedInvestigations1/170/160/170/18
Lymphocyte count decreasedInvestigations1/170/160/170/18

Baseline characteristics

The SES included all subjects who were exposed to investigational product (IP) at least once.

Age, Continuous
Age, Continuous(years)Group 1: Dose 1 NT201Group 2: Dose 2 NT201Group 3: Dose 3 NT201Group 4: PlaceboTotal
Mean51.2 ± 7.8349.8 ± 8.7149.9 ± 7.5950.3 ± 6.8650.3 ± 7.59
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Dose 1 NT201Group 2: Dose 2 NT201Group 3: Dose 3 NT201Group 4: PlaceboTotal
Female1616141763
Male10315
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Dose 1 NT201Group 2: Dose 2 NT201Group 3: Dose 3 NT201Group 4: PlaceboTotal
American Indian or Alaska Native10001
Asian00112
Native Hawaiian or Other Pacific Islander00000
Black or African American21104
White1415151660
More than one race00011
Unknown or Not Reported00000
08

Study locations

7 sites
  • Merz Investigation Site #0010170
    Washington D.C., District of Columbia 20037, United States
  • Merz Investigational Site #0010453
    Aventura, Florida 33180, United States
  • Merz Investigation Site #0010470
    Coral Gables, Florida 33143, United States
  • Merz Investigation Site #0010105
    Metairie, Louisiana 70006, United States
  • Merz Investigation Site #0010471
    Verona, New Jersey 07044, United States
  • Merz Investigation Site #0010469
    New York, New York 10022, United States
  • Merz Investigation Site #0010405
    New York, New York 10028, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Oct 2023, 6 months.

Results were first posted in Nov 2026, 3 years after primary completion. A results delay was requested in Oct 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Mar 17, 2023
StartActual
Mar 22, 2023
Primary completionActual
Oct 19, 2023
CompletionActual
Jan 24, 2024
Results delay requested
Oct 17, 2024
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange From Baseline on the Merz Aesthetic Platysma Scale-Dynamic (MAPS-D) Score at Maximum Contraction as Assessed Live by the Investigator at Visit 4 (V4)Week 2Time frame: Baseline (Screening Visit), Week 2 (V4) → Baseline and Week 2
Nov 10, 2026
Documents
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedChange From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Subject at V4Week 2Time frame: Baseline (Screening Visit), Week 2 (V4) → Baseline and Week 2
  • EditedNumber of Subjects With Related Treatment Emergent Adverse Events (Related TEAEs)Time frame: Baseline up to Week 17/End of Study → From first dose of study drug up to Week 17
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange From Baseline on the Merz Aesthetic Platysma Scale-Dynamic (MAPS-D) Score at Maximum Contraction as Assessed Live by the Investigator at Visit 4 (V4)Week 2Time frame: Baseline (Screening Visit), Week 2 (V4) → Baseline and Week 2
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedChange From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Subject at V4Week 2Time frame: Baseline (Screening Visit), Week 2 (V4) → Baseline and Week 2
    • EditedNumber of Subjects With Related Treatment Emergent Adverse Events (Related TEAEs)Time frame: Baseline up to Week 17/End of Study → From first dose of study drug up to Week 17
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05773053
Responsible party
Sponsor
First posted
Mar 17, 2023
Start date
Mar 22, 2023
Primary completion
Oct 19, 2023
Completion
Jan 24, 2024
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

Merz Medical Expert
study director · Merz North America, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: incobotulinumtoxinA

Start the discussion